Analyzing Nuvation Bio (NYSE:NUVB) & Surrozen (NASDAQ:SRZN)

Surrozen (NASDAQ:SRZN) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares Surrozen and Nuvation Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$11.51 million	19.16	-$242.03 million	($40.55)	-0.47
Nuvation Bio	$169.90 million	12.62	-$204.63 million	($0.44)	-13.88

Nuvation Bio has higher revenue and earnings than Surrozen. Nuvation Bio is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Surrozen and Nuvation Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Insider & Institutional Ownership

66.6% of Surrozen shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Surrozen has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Surrozen and Nuvation Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1	1	4	1	2.71
Nuvation Bio	1	2	10	0	2.69

Surrozen presently has a consensus price target of $45.00, indicating a potential upside of 136.84%. Nuvation Bio has a consensus price target of $13.00, indicating a potential upside of 112.94%. Given Surrozen’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Surrozen is more favorable than Nuvation Bio.

Summary

Surrozen beats Nuvation Bio on 8 of the 15 factors compared between the two stocks.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.